Nabi Pharmaceuticals files $175 million shelf

By Ted A. Knutson

Washington, Dec. 7 - Nabi Pharmaceuticals registered a shelf for up to $175 million in debt securities, warrants, preferred stock and common stock with the Securities and Exchange Commission in an S-3 filing Tuesday.

The registration leaves open the potential for convertibles.

Boca Raton, Fla.-based Nabi, which specializes in medicines for infectious, autoimmune and addictive diseases, said it will use proceeds for any offerings authorized by the shelf for general corporate purposes including clinical trials, research and development expenses, new acquisition and licensing costs, general and administrative expenses, and working capital.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.